Business
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the commercial launch of VELSIPITY® (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region. As a once-daily oral therapy w
About this update from Everest Medicines Ltd.
[{"type":"text","content":"SHANGHAI, March 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the commercial launch of VELSIPITY® (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region. As a once-daily oral therapy with sustained efficacy, a favorable safety profile, and the ability to achieve deep mucosal healing, VELSIPITY® offers a novel treatment option for patients with moderately to severely active ulcerative colitis (UC), supporting long-term disease control and improved outcomes.","length":846,"tagName":"p"},{"type":"text","content":"VELSIPITY® is a next-generation, highly selective S1P receptor modulator with best-in-disease potential and strong first-line treatment recommendations in leading international guidelines. China's National Medical Products Administration (NMPA) has approved VELSIPITY® on February 2, 2026, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.","length":511,"tagName":"p"},{"type":"text","content":""With the first prescription now issued, VELSIPITY® is being incorporated into routine clinical practice, providing physicians with an innovative treatment option for patients living with UC who continue to face ongoing disease challenges, " said Prof. Chen Minhu, Academic Leader of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University. "Results from multiple global clinical studies have demonstrated that VELSIPITY® delivers meaningful clinical benefits, including rapid onset of action, long-lasting clinical remission, steroid-free remission, and deep mucosal healing, with a favorable safety profile. In the ENLIGHT UC study, the largest Asian multicenter Phase 3 clinical study, the clinical remission rate at week 40 of the maintenance period reached 48.1%, and the deep mucosal healing rate reached 51.9%, with an endoscopic mucosa...